Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1711-1720 Newer>

The Motley Fool January 26, 2005 Charly Travers	Call Cubist in the Morning Strong drug sales provide a dose of good medicine for this pharmaceutical.
The Motley Fool January 26, 2005 Charly Travers	Protein Design Muscles Up Biotech company buys itself a bigger future. The company announced that it had acquired privately held ESP Pharma for $300 million cash and $175 million stock.
The Motley Fool January 26, 2005 Stephen D. Simpson	St. Jude Is No Lost Cause The No. 3 cardiology company posts solid growth because of continuing implantable cardioverter defibrillator (ICD) market share gains.
The Motley Fool January 26, 2005 Stephen D. Simpson	Lilly's No Wallflower The drugmaker posts tepid results as it bides time before new products hit the market. Lilly's valuation suggests that Wall Street has faith that those new drugs will come through.
The Motley Fool January 26, 2005 Rich Duprey	Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits.
The Motley Fool January 25, 2005 Stephen D. Simpson	Prognosis Good for Merck The pharmaceutical weathered a tough year but should ride out its Vioxx troubles. While strict value investors may be put off, risk-tolerant investors can buy these shares today.
The Motley Fool January 25, 2005 Rich Smith	ViaCell's Costly Mistake Cord blood harvester neglects to collect the cash with an undervalued IPO.
The Motley Fool January 25, 2005 Stephen D. Simpson	Schering-Plough Turning a Corner The troubled pharmaceutical company begins to show signs of life. Investors looking for a more stable play would do well to look at other shares instead.
HBS Working Knowledge January 24, 2005 Martha Lagace	Entrepreneurial Hospital Pioneers New Model A "Robin Hood" cardiac hospital in India---which charges wealthy patients, yet equally welcomes the destitute---is cited as an exciting example of entrepreneurship in the subcontinent.
BusinessWeek January 31, 2005 Kerry Capell	No Relief For AstraZeneca More bad news about potential blockbusters weakens Europe's third-largest drugmaker. Analysts say the only thing keeping Astra's shares from going into free fall is the mounting speculation that GSK might make a play for the troubled drugmaker.
<Older 1711-1720 Newer> Return to current articles.